Logos Analytics is our in-house data science platform developed to help predict clinical trial outcomes.
Biotechnology is a data driven sector. Clinical trial outcomes dictate value creation or destruction, particularly for small and mid-sized companies. The role of data science at Logos is to simulate clinical data for a given trial and apply statistical tests to replicate what the company and FDA will do to determine if the trial was statistically significant and clinically meaningful (or not). There is no formulaic or algorithmic approach to definitively state that a trial will succeed or fail. Each investment presents its own unique project, data and frameworks to consider.
The inputs we use are varied based on available data. The analyses are dependent on the trial design as well as our assumptions and questions. However, the output is effectively the same – a refined probability of success that allows Logos to better understand the risk and the likelihood of reward. Logos Analytics tracks clinical data, builds comprehensive event calendar maps, and sources inputs from a wide variety of academic literature and drug development programs. Although we primarily use Logos Analytics to help determine probability of success or failure in clinical trials, we sometimes share our analysis with management teams.